Kornimate/medical-research-clean huggingface dataset:
asian myeloproliferative neoplasm (mpn) registry

Conditions: Myeloproliferative Neoplasm; Polycythemia Vera; Essential Thrombocythemia; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Primary Myelofibrosis; Primary Myelofibrosis, Prefibrotic Stage; Primary Myelofibrosis, Fibrotic Stage

Summary: this is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

this is a multinational, multicenter, prospective and retrospective, observational, cohort registry of patients with mpn. the registry mainly involves study centres in asia including but not limited to hong kong, singapore, malaysia, taiwan, korea and thailand. clinicopathologic characteristics, cytogenetic characteristics, mutational characteristics, treatment characteristics, outcomes and survivals of asian patients mpn diagnosed between 2010-2025 will be collected to establish clinical registry. data on the clinicopathologic characteristics, cytogenetics, mutational profile, prognostic scoring treatment characteristics, responses to treatment, outcome and survivals will be collected through routine clinic visits and/or reviewing medical records. data will be collected at diagnosis, and approximately every 6 months thereafter (for prospective data) and at progression until death/study termination.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old at the time of diagnosis of mpn. 2. subject was diagnosed with one of the following disorders according to the 2017 who classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 who classification): 1. polycythaemia vera 2. essential thrombocythemia 3. primary myelofibrosis, pre-fibrotic/early stage 4. primary myelofibrosis, overt fibrotic stage 5. post-polycythaemia vera myelofibrosis 6. post-essential thrombocythaemia myelofibrosis 7. mpn-unclassifiable 3. all subjects need to provide informed consent. exclusion criteria: a subject will not be eligible if he/she meets any of the following criteria: 1. subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia bcr-abl1 positive, under the 2017 who classification

Keywords: myeloproliferative neoplasm epidemiology outcome prognostic factors
youth mental health recovery in the family after inpatient stay

Conditions: Caregiver Burden; Family Characteristics; Parent-Child Interactions

Summary: the goal of this longitudinal mixed-methods study is to investigate caregiver strain, family processes and health outcomes after youth psychiatric inpatient treatment. caregivers of youth who received inpatient treatment for mental health problems will complete a survey at three timepoints (baseline, 3- and 6- month followup) reporting on youth outcomes, caregiver well-being, and family processes. qualitative interviews on caregivers' challenges, needs, and resources around the return to home care are conducted with a subsample (target n = 10) of participants. the main research questions (rqs) are: rq 1: do family processes contribute to youth mental health outcomes after discharge from inpatient treatment? rq 1a: what family-level risk factors predict youth readmission to inpatient treatment? rq 1b: do family processes predict youth mental health trajectories over time? rq 2: is there a reciprocal relationship between youth mental health problems and caregiver burden? rq 2a: do family processes mediate the association between caregiver burden and youth mental health problems? rq 3: how do caregivers experience their children's return to home care? rq 3a: what challenges and needs do caregivers report? rq 3b: what types of follow-up services do families receive and/or have access to? rq 3c: how do caregivers cope with ongoing difficulties in the post-discharge period?


Eligibility criteria:
inclusion criteria: * 18 years or older * primary caregiver of a child or adolescent aged 7-21 years of any gender who received inpatient treatment in a psychiatric institution in germany, austria, or switzerland (min. 24 h stay) within the past month (regardless of the diagnosis or the reason for the treatment, respectively) * lived with the child or adolescent in the same household since discharge exclusion criteria: * another caregiver of the same child has already participated in the study * insufficient knowledge of german
extracorporeal shock wave therapy versus high power laser therapy for the treatment of females with calcaneal spur

Conditions: Calcaneal Spur

Summary: purpose: to compare the effect of extracorporeal shock wave therapy and high-power laser therapy for the treatment of patients with calcaneal spur background: calcaneal spur is a common musculoskeletal disorder of the foot that affect the quality-of-life conservative treatment modalities include, cold application, platelet-rich plasma therapy (prp), shoe modification, therapeutic ultrasound, extracorporeal shock wave therapy (eswt), laser therapy (lllt) are commonly used in the treatment of calcaneal spur. hypotheses: there will be difference between extracorporeal shock wave therapy and high- power laser therapy on pain intensity in patients with calcaneal spur there will be difference between extracorporeal shock wave therapy and high- power laser therapy on function in patients with calcaneal spur. there will be difference between extracorporeal shock wave therapy and high- power laser therapy on the size of calcaneal spur in patients with calcaneal spur. research question: is there any difference between the effect of extracorporeal shock wave therapy and high-power laser on calcaneal spur?


Eligibility criteria:
inclusion criteria: diagnosed with calcaneal spur based on clinical examination and radiological findings. exclusion criteria: were as follows: acute trauma to the foot, history of fracture or surgery, lower extremity neurological deficit, polyneuropathy, radicular pain, autoimmune diseases tumor, thrombosis, soft tissue or bone infection, or skin disorder.
a study of the helix surgical system in primary open-angle glaucoma (poag) and cataract (helix)

Conditions: Primary Open Angle Glaucoma; Cataract

Summary: a study to assess the safety of the helix surgical system in cataract surgery and to gain early evidence of its effectiveness in lowering intraocular pressure (iop) in subjects with mild to moderate primary open-angle glaucoma (poag) and cataracts.

to assess the safety of the helix surgical system with cataract surgery and gain early evidence on intraocular pressure (iop) -lowering effectiveness in subjects with mild-moderate primary open-angle glaucoma (poag) and cataract.

Eligibility criteria:
inclusion criteria: * male or female subjects, 45 years or older * visually significant age-related cataract. * intraocular pressure (iop) at the screening visit not exceeding 33 mmhg and at least 21 mmhg for unmedicated eyes or 16 mmhg if medicated (1 to 4 ocular hypotensive medications - fixed combinations count as the number of components), with a stable medication regimen for ≥2 months. * diagnosed with mild to moderate primary open angle glaucoma (poag). exclusion criteria: * any of the following prior ocular procedures: * laser trabeculoplasty ≤180 days prior to baseline * durysta ≤12 months prior to baseline * any implanted glaucoma device * prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy * ciliary ablation including endoscopic cyclophotocoagulation (ecp), cyclophotocoagulation or cpc (g probe), high intensity focused ultrasound (hifu), * 180 days prior to baseline * retinal laser procedure ≤3 months prior to baseline * any form of glaucoma other than poag * use of topical ocular steroids. * clinically significant concurrent ocular pathology or systemic medical condition which, in the investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period or interfere with compliance to elements of the study protocol * history of penetrating keratoplasty or another corneal transplant * endothelial cell density \ 65). * retrobulbar tumor, thyroid eye disease, sturge-weber syndrome or any other type of condition that may cause elevated episcleral venous pressure. * bcva of logmar 0.4 (20/50) or worse in the study eye not due to cataract * bcva of logmar 0.6 (20/80) or worse in the non-study eye not due to cataract.
pronase in improving endoscopic mucosal clarity during colonoscopy for patients with colitis

Conditions: Pronase; Mucosal Clarity

Summary: pronase is a proteolytic enzyme known for its ability to clear mucus by breaking down its main component, mucin, through enzymatic hydrolysis. this property makes it useful in gastroscopy, where it is employed to improve the visibility of the mucosal surface during endoscopic examinations. given the same mechanism, pronase may also be beneficial in enhancing mucosal clarity during colonoscopy. this multicenter, prospective, double-blind randomized controlled trial is designed to assess the effectiveness and safety of pronase in improving mucosal visibility in patients with colitis during endoscopy.


Eligibility criteria:
inclusion criteria: * patients presenting with intestinal inflammation during colonoscopy, accompanied by mucus obscuring visualization, were included, particularly those with inflammatory bowel disease (ibd), regardless of the presence or absence of clinical symptoms such as abdominal pain, diarrhea, hematochezia, or mucoid stools. * researchers assessed the current health status of potential participants to ensure they could tolerate colonoscopy (based on physical examination and medical history). * age range was 18-75 years (inclusive). * participants provided written informed consent to participate voluntarily. exclusion criteria: * participants with known hypersensitivity or allergy to the study medication. * participants with peritonitis, intestinal obstruction, severe intestinal infection, or radiation colitis. * participants who did not exhibit intestinal mucus obscuring endoscopic visualization during colonoscopy. * participants with severe cardiovascular, pulmonary, neurological, or renal disease, or those deemed unfit for colonoscopy. * participants who did not provide written informed consent or lacked the capacity to do so. * pregnant or breastfeeding women. * participants who had taken antiplatelet medications (e.g., aspirin, clopidogrel) or had abnormal coagulation function within 7 days prior to colonoscopy. * participants currently participating in other clinical observation trials or who had participated in another clinical trial within 60 days.

Keywords: pronase colonoscopy mucosal clarity colitis ulcerative colitis crohn&#39;s disease inflammatory bowel disease
the effect of paravertebral block with dexamethasone on intraoperative and postoperative analgesia in children undergoing surgery for coarctation of aorta

Conditions: Coarctation of Aorta

Summary: anesthetic management for surgery of aortic coarctation needs special care due to severe pain during lateral thoracotomy incision, the intraoperative hemodynamic instability related to skin incision at lateral thoracotomy, clamping and declamping of the aorta, needs of large doses of analgesia perioperative, needs of vasodilators. also, postoperative care of the patients after repair is very important issue. the investigators will compare the effect of para-vertebral block with bupivacaine alone or with dexamethasone on intra and postoperative analgesia.

the patients will be divided randomly by sealed envelope into 2 equal groups. group i (n=30) will receive paravertebral block with 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) and group ii (n=30) will receive paravertebral block with 0.5mg/kg 0.25% bupivacaine and 0.1mg/kg dexamethasone.intraoperative fentanyl needs, intra and postoperative hemodynamics and ops pain scores will be recorded. possible risks as hypertension will be treated by nitroglycerin infusion 0.5ug/kg/min or tachycardia (hr more than 20% than baseline) will be managed by additional doses of fentanyl 1-2ug/kg, bradycardia (20% decrease from the baseline) will be managed by atropine 0.02mg/kg. also, the complications of paravertebral block as peridural and intravascular injection can be avoided by careful aspiration before injection and injection while visualization of the needle by u/s.

Eligibility criteria:
inclusion criteria: * 4m-6 years males and females scheduled for surgery for coarctation of the aorta exclusion criteria: * patients with associated other cardiac anomalies (e.g. vsd), patients with airway abnormality, patients with heart failure, patients with endocrine disorders, patients with history of convulsions, neurological disorder, hepatic, renal and neuromuscular diseases, coagulopathy, history of hyperthermia, infection at site of the block and family history of hypersensitivity
safety of topical tranexamic acid in total joint arthroplasty in high risk patients

Conditions: Pulmonary Embolism; Deep Vein Thrombosis; Stroke; Myocardial Infarction

Summary: to evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied tranexamic acid in total joint arthroplasty.

tranexamic acid (txa) has been used successfully to stop bleeding after dental procedures, removal of tonsils, prostate surgery, heavy menstrual bleeding, and eye injuries, as well as in patients with hemophilia. intravenous txa has also been shown to reduce blood loss, reduce transfusion requirements, and decrease length of stay for patients undergoing total knee arthroplasty and total hip arthroplasty. these benefits occur without increasing risks of thromboembolism events such as pulmonary embolism, deep venous thrombosis, myocardial infarctions, and cerebrovascular events in patients without history of, or risk factors for thromboembolic disease. topical txa in tja has also been demonstrated to show the above benefits without any increase risks, as well as systemic absorption of the medication that is below the effective therapeutic plasma concentration. preliminary retrospective studies has demonstrated that iv txa to be safe and effective in patients with risk factors for thromboembolic events and patients with american society of anesthesiologists score iii or iv. currently, there are no prospective studies on the use of either iv or topical txa in these higher risk patients. the goal of this study is to evaluate whether there is a difference in symptomatic thromboembolism events in the subset of patients with a history of, or risk factors for thromboembolic disease for topically applied txa in total joint arthroplasty (tja).

Eligibility criteria:
inclusion criteria: presence of one or more of seven risk factors for thromboembolic events - prior dvt, pe, mi, cva, coronary artery stent placement, cabg, or prothrombotic condition (factor v leiden deficiency, protein c deficiency, antiphospholipid syndrome, etc). exclusion criteria: simultaneous bilateral, hip resurfacing, partial knee, and revision arthroplasties
improving geriatric drug safety in underserved practices

Conditions: Cardiovascular Diseases

Summary: the purpose of this study is to determine whether a crm (adapted crew resource management approach proven successful in aviation as well as some inpatient medical settings) intervention is effective for reducing medication errors among older adults in primary care settings.

adverse drug events (ades) are among the most common and serious medication use concerns among older patients in primary care practices, yet they are often preventable. this translational research into practice (trip) pilot study uses a randomized trial to evaluate the effect of a site-level intervention in a sample of practices in medically underserved communities within the upstate new york practice based research network (unynet). these sites are located in rural and urban areas and include an over-sample of minority patients. the specific aims of this study are to: 1. examine the feasibility of objectively assessing the impact of a crm (adapted crew resource management approach proven successful in aviation as well as some inpatient medical settings) intervention on reducing medication errors among geriatric patients in primary care settings; and 2. assess office staff internalization and application of crm principles for reducing geriatric medication errors in primary care settings by examining changes in safety attitude constructs achieved 1. with a practice enhancement assistant (pea) and 2. without a pea. outcomes measured for aim #1 will be change in number, severity, consequence, and stage of process of preventable ades. outcomes for aim # 2 will be change in safety climate, teamwork climate, stress recognition, and working conditions. fifteen sites will be randomized into one of three intervention arms: usual care, crm only, or crm plus a pea. a random sample of charts of older adults (aged \>64) with cardiovascular disease will be reviewed for adverse drug events over prior-year periods at baseline and post-intervention endpoints. participatory research methods will be used to assess provider- and staff-identified barriers to implementation. this study will test the feasibility of incorporating pea's into the practice setting to improve geriatric medication safety. the information gathered will serve as a basis for an ongoing translational research program that will lead to an ro1 application.

Eligibility criteria:
practice inclusion criteria: * practice must located in health professional shortage area or physician scarcity area. * practice must be a member of the western new york practice-based research network practice exclusion criteria: * none patient inclusion criteria (for chart review): * aged \>64 * cardiovascular disease * seen at the practice within the past year patient exclusion criteria (for chart review): * none

Keywords: medication safety adverse drug events preventable adverse drug events culture of safety failure modes and effects analysis teambuilding
comparison of autologous serum and umbilical cord serum eyedrops for dry eye syndrome

Conditions: Dry Eye Syndrome

Summary: to compare the therapeutic effect between autologous serum and umbilical cord serum eyedrops in the treatment of severe dry eye syndrome.

ninety-two eyes of 48 patients with severe dry eye syndrome (34 eyes of 17 patients with sjögren's syndrome and 58 eyes of 31 patients with non-sjögren's syndrome) were treated with either 20% autologous serum (41 eyes of 21 patients) or umbilical cord serum eyedrops (51 eyes of 27 patients). symptom scoring, corneal sensitivity test, tear film break-up time (but), schirmer test, tear clearance rate (tcr), corneal fluorescein staining, and conjunctival impression cytology were performed before and 1 month and 2 months after treatment.

Eligibility criteria:
inclusion criteria: * patients with severe dry eye syndrome who were refractory to conventional treatments and had symptoms of dry eye for more than 3 months * low tear film break-up time (but, \< 5 sec) * low schirmer test (5 mm) * positive fluorescein or rose bengal vital staining (≥ 3) exclusion criteria: * active ocular infection or inflammation not associated with dry eye * contact lens wear * ocular allergy * ocular surgery within the recent 3 months * lid or lash abnormalities * pregnant or lactating women
ai based real time detection of endometriosis lesions

Conditions: Endometriosis

Summary: development of ai-based approaches for automated real-time detection of endometriosis lesions using endoscopic image and video material.

in the field of endometriosis, artificial intelligence (ai) has been used for diagnoses or even predictions of endometriosis before confirmation through laparoscopy. ai's significant potential in minimally invasive surgery lies in automatic image analysis, aiding in the detection of structures or anomalies based on image data. this offers the potential to detect endometriosis lesions during laparoscopy regardless of the indication. training and creating such ai models are done using machine learning algorithms based on annotated data. these training data consist of image data with pixel-level annotations of the content that the model should detect. deep learning (dl) algorithms have proven effective in image analysis, relying on neural networks to autonomously fill them with the most critical decision criteria for correct analysis of the image content. the trained ai model can then be applied to unknown data, providing the probability of detecting a structure for each pixel. possible visual outputs of the model include outlining the detected content or segmenting, assigning predefined content to each pixel. the quality of the model depends crucially on a sufficiently large number and quality of training data. quality includes correct annotation of data to prevent the model from learning errors. diversifying image data by including negative examples in the training and test datasets is equally important. the f1-score is used as a measure of the model's quality, combining precision (p) with recall (r) to a value between 0 and 1, based on an annotated test dataset. the goal is to achieve a high f1-score through the selection of training data and an appropriate dl algorithm. parameters like image preparation optimization or dl algorithm parameters such as selecting different neural networks can improve the f1-score. the number of required training data for a good ai model depends on the complexity of the question and the number of contents to be detected, as the model can only recognize learned content. it is possible to iteratively adjust the selection of training data for different questions based on the achieved f1-scores after each training and testing. if necessary, the number of training data can be increased, and problematic image data, such as missing annotations, can be identified and corrected based on the results.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * written consent after explanation * indication for surgical treatment of endometriosis exclusion criteria: * expected lack of patient compliance or inability of the patient to understand the purpose of the clinical trial * absence of patient consent * malignancies
a retrospective study of the effects of molecular diagnostics on wound care outcomes

Conditions: Wounds

Summary: a retrospective molecular diagnostic review on wound care outcomes between two time periods. the time periods include june, july, august of 2008 and june, july, august of 2009. the retrospective review would analyze the days of healing during those two timeframes, upon the introduction of molecular diagnostic testing.


Eligibility criteria:
inclusion criteria: * a patient record captured during june, july, august 2008 and june, july, or august of 2009. exclusion criteria: * a patient record captured outside the time frame of june, july august 2008 or june, july, august of 2009.

Keywords: retrospective data collection